Sardar Imam, MBBS
Dr. Imam is currently practicing as a hematologist and oncologist at the Four Corners Cancer Institute in Farmington, New Mexico, where he also serves as the director of the research division.
He completed his basic schooling at the prestigious Aitchison College, Lahore. He t from Aga Khan University, Karachi, the top-ranked medical school in Pakistan. In pursuing medicine, he followed his father, an eminent professor of medicine and principal (dean). He also derives inspiration from his grandfather, himself a Professor Emeritus, a former principal (dean) of a medical school, and president of the Pakistan Medical and Dental Council.
Dr Imam graduated from medical school with honors, achieved a 99th percentile in all of his United States Medical Licensure Examinations, and then proceeded to complete his internal medicine residency at the University of Texas Medical School at Houston. His training in hematology and oncology was at Baylor College of Medicine, Houston Methodist Hospital, and M.D. Anderson Cancer Center, all highly ranked institutions located in the Texas Medical Center.
Dr. Imam ranked among the top ten percent of exam-takers in his internal medicine, oncology as well as hematology certification examinations conducted by the American Board of Internal Medicine. He achieved the unique distinction of attaining the maximum possible standardized score of 800 in the hematology certification exam. He is also specialty certified in medical oncology from the Federation of Royal College of Physicians, United Kingdom.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Cardinal HealthDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Boston BiomedicalDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:PharmacyclicsDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:ExelixisDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Astra ZenicaDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:QED TherapeuticsDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:AbbVieDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Janssen PharmaceuticalsDate added:01/03/2024Date updated:01/03/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:SeaGenDate added:01/03/2024Date updated:01/03/2024